Clinical data in patients with RA suggested to be representative for the entire RA population
| All (n=287) | Women (n=235) | Men (n=52) | |
|---|---|---|---|
| Except where otherwise indicated, values are mean (SD). | |||
| *The number varies from 287 in all patients or from 235 in women patients owing to missing values; †the mean ESR and CRP values are based on two measurements performed two years apart; ‡oestradiol, bisphosphonates or calcitonin; BMI=body mass index; RF=rheumatoid factor positive; VAS=visual analogue scale; HAQ=Health Assessment Questionnaire, mHAQ=modified Health Assessment Questionnaire; ESR=erythrocyte sedimentation rate; CRP=C reactive protein. | |||
| Demographic variables: | |||
| Age (years) | 57.6 (11.0) | 56.8 (11.0) | 61.5 (10.2) |
| Body weight (kg) | 68.4 (12.9) | 65.8 (11.5) | 80.2 (12.4) |
| Body height (cm) | 167.8 (7.8) | 165.5 (5.9) | 178.2 (6.8) |
| BMI (kg/m2) | 24.2 (4.1) | 24.0 (4.2) | 25.2 (3.2) |
| Menopause | – | 163 (69.4%) | – |
| Menopause age (years) | – | 48.7 (4.8) | – |
| Current smoker (n=282)* | 100 (35.5%) | 80 (34.6%) | 20 (39.2%) |
| Disease variables: | |||
| Disease duration (years) | 15.4 (9.4) | 15.5 (9.5) | 14.7 (8.6) |
| RF positive (n=269)* | 134 (49.8%) | 109 (50.0%) | 25 (49.0%) |
| Global assessment score (VAS 0–100 mm) (n=259)* | 23.7 (18.7) | 23.7 (18.4) | 23.7 (20.0) |
| HAQ (range 0–3) | 0.99 (0.67) | 1.01 (0.66) | 0.91 (0.70) |
| mHAQ score (range 1–4) | 1.60 (0.51) | 1.61 (0.52) | 1.55 (0.48) |
| Mean ESR† (n=285)* | 20.8 (15.9) | 20.7 (15.5) | 21.4 (17.7) |
| Mean CRP† (n=238)* (mg/l) | 15.8 (13.0) | 15.3 (12.0) | 18.0 (16.3) |
| Treatment variables: | |||
| Current prednisolone use (n=287) | 125 (44%) | 102 (44%) | 23 (44%) |
| Ever prednisolone use (n=287) | 189 (66%) | 157 (667) | 32 (62%) |
| Duration of prednisolone use among current users (months) (n=122) | Median 78 (range 1–500) | Median 84 (range 1–480) | Median 60 (range 18–500) |
| Cumulative prednisolone dose in past 12 months (g) (n=129) | 2.1 (1.4) | 2.1 (1.4) | 2.1 (1.5) |
| Current use of oestradiol (n=230)* | – | 88 (38%) | – |
| Current use of any antiresorptive osteoporosis treatment‡ (n=283)* | 107 (38%) | 104 (45%) | 3 (6%) |